ATL Technology: MD&M West 2024: Tech Talk and Meeting Registration
ARUP’s Julio Delgado, MD, MS, Selected as Inaugural Harry R. Hill, MD, Presidential Endowed Chair-Holder
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients.
Collaboration with Kenya Ministry of Health National Cancer Institute Aims to Expand Access to Diagnostics, Reduce Cervical Cancer Rates
Nusano Names Rohan Jain as Commercial General Manager.
Gibco CTS Cellmation Software digitally connects instruments from across Thermo Fisher’s cell therapy portfolio to streamline and automate manufacturing
Local Coverage Determination would result in contracted coverage for an estimated additional five million Medicare patients with Type 2 diabetes and early-stage chronic kidney disease
First Patient Enrolled in Merit Medical’s MOTION Study
bioMérieux acquires LUMED to reinforce its software portfolio in the fight against antimicrobial resistance
By allowing Carterra’s superior epitope, binding affinity, and kinetic information to occupy the same view as sequence information, the IGX Platform enables faster, better decision-making in therapeutic discovery.
National Registry Names Intermountain Health’s Transplant Program as Nation’s Top Program for Successfully Matching Donated Kidneys to Patients
Merit Medical Announces Process for Chief Executive Officer Succession Planning
Spectrum Solutions Names Bill Phillips as New Chief Executive Officer
$40 million capex, 155 jobs, Project Orange
LEHI, Utah /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical trial evaluating its lead candidate, HT-6184, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS). HT-6184 is a selective and orally bioavailable first-in-class […]
BD MiniDraw™ Capillary Blood Collection System Enables Lab-Quality Blood Testing from Less Invasive Method than Venous Collection in More Convenient Locations
Utah Business recently featured Halia Therapeutics co-founder David Bearss in their Founder Series
SINGAPORE–(BUSINESS WIRE)–RxCell, a pioneering biotech company focusing on cellular therapeutics for age-related diseases, today proudly announces a $4,600,000 investment commitment from DMR Global Venture LLC and Regenosis. Building on the strength of collaboration with National University of Singapore, this fresh investment accentuates RxCell’s resolute drive to revolutionize age-related disease treatment. “We’re thrilled to align with […]
Culmination Bio has over 40 years of biospecimen data and counting, paired with clinical data from patient EHRs, making recruitment for pharmaceutical research almost instantaneous. St. George, Utah — (November 30, 2023) — Culmination Bio, a company building the largest disease-agnostic patient data intelligence platform, today announced a $10 million investment from Merck Global Health […]
SALT LAKE CITY, Dec. 6, 2023 /PRNewswire/ — Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal […]
BD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems
Next-Generation Microcatheter for Embolic Agent Delivery Cleared by the FDA
SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success
Seek Labs Announces Completion of Office Expansion to Support Business Growth
Metabolexis focuses on GLP-1 weight loss and type 2 diabetic drug discoveries to improve accessibility and meet unprecedented demand.
LED BY CLARKE CAPITAL, THE NEW FUNDING ROUND WILL ACCELERATE THE COMPANY’S DRUG DISCOVERY PIPELINE
Myriad Genetics Celebrates One Million SneakPeek® Results Shared with Expectant Parents
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests
PhotoPharmics Secures $16 Million Investment Led by Kickstart to Fund Pivotal Clinical Trial for FDA Market Authorization
Seek Labs’ integrated molecular diagnostic platform brings true point-of-care testing to the patient.
BioUtah yesterday held its 2023 Utah Life Sciences Summit, presented by Mayer Brown. Every year, the Summit is the largest gathering of Utah’s life sciences industry. This year was no exception. Following welcome remarks from Gov. Spencer Cox, a distinguished line-up of top executives addressed a packed house. Keynote speaker, Joseph Smith, chief scientific officer […]
